灯盏花素注射液治疗稳定期COPD的临床疗效及对TGF-β1含量、TβRI、Smad2、Smad3表达水平的影响  

Clinical efficacy of Breviscapine injection on stable COPD and its effect on TGF-β1 content and TβRI,Smad2,Smad3 expression levels

作　　者：王思颖 赵琦[1] 杨欣[1] 王虹 芦阳 WANG Siying;ZHAO Qi;YANG Xin;WANG Hong;LU Yang(Department of Pharmacy,Hebei Qinhuangdao Traditional Chinese Medicine Hospital,Qinhuangdao,Hebei,China,066000)

机构地区：[1]河北秦皇岛市中医医院药剂科,河北秦皇岛066000

出　　处：《分子诊断与治疗杂志》2023年第2期335-338,343,共5页Journal of Molecular Diagnostics and Therapy

基　　金：秦皇岛市科学技术研究与发展计划(202004A125)。

摘　　要：目的 研究灯盏花素注射液治疗稳定期慢性阻塞性肺疾病(COPD)的临床疗效及对血清转化生长因子-β1(TGF-β1)含量、外周血TβRI、Smad2、Smad3表达水平的影响。方法 选择2019年4月至2021年4月期间河北秦皇岛市中医医院收治的110例稳定期COPD患者进行研究,分为接受常规西医药物联合灯盏花素治疗的观察组、接受常规西医药物治疗的对照组。治疗后12周时评价临床疗效,进行慢阻肺评估测试(CAT)和慢阻肺生活质量评价表(QLICD-COPD)评价,检测肺功能指标肺功能仪检测一秒用力呼气容积(FEV1)、用力肺活量(FVC)、每分钟最大通气量(MVV)及血清TGF-β1、外周血TβRI、Smad2、Smad3的mRNA表达水平;治疗后随访1年,观察COPD急性发作(AECOPD)和再入院的发生情况。结果 治疗后12周时,观察组的治疗总有效率、QLICD-COPD评分、FEV1、FEV1/FVC、MVV水平高于对照组(χ^(2)=7.781,P<0.05),CAT评分、血清TGF-β1含量、外周血TβRI、Smad2、Smad3的mRNA表达水平低于对照组,差异有统计学意义(χ^(2)=7.781,t=7.400、4.114、4.803、5.369、3.818、13.007、8.654、4.929、5.623,P<0.05);治疗后随访1年,随访期间观察组患者AECOPD的累积发生率和再住院的累积发生率均低于对照组,差异有统计学意义(χ^(2)=4.325、4.145,P<0.05)。结论 灯盏花素注射液治疗稳定期COPD显著改进疗效、改善肺功能和生活质量,抑制TGF-β1/Smad通路灯盏花素注射液的治疗作用相关。Objective To study the clinical efficacy of Breviscapine injection on stable chronic obstructive pulmonary disease(COPD)and its effect on transforming growth factor-β1(TGF-β1)content,TβRI,Smad2,Smad3 expression levels. Methods 110 patients with stable COPD admitted to our hospital from April 2019 to April 2021 were collected for retrospective cohort study. They were divided into the observation group receiving conventional western medicine combined with Breviscapine and the control group receiving conventional western medicine. 12 weeks after treatment,the clinical efficacy was evaluated,the chronic obstructive pulmonary disease assessment test(CAT)and the chronic obstructive pulmonary disease quality of life assessment form(QLICD-COPD) were evaluated,the pulmonary function indexes forced expiratory volume on first second(FEV1),forced vital capacity(FVC),maximum ventilation volume per minute(MVV)and serum TGF-β1 contents,the mRNA expression levels of TβRI,Smad2 and Smad3 in peripheral blood were detected. The patients were followed up for 1 year after treatment and the incidence of acute exacerbation of COPD(AECOPD) and readmission were observed. Results At 12 weeks after treatment,the total effective rate,QLICD-COPD score,FEV1,FEV1/FVC and MVV levels in the observation group were higher than those in the control group,and the CAT score(χ^(2)=7.781,P<0.05),serum TGF-β1content,the mRNA expression levels of TβRI,Smad2 and Smad3 in peripheral blood were lower than those in the control group(χ^(2)=7.781,t=7.400,4.114,4.803,5.369,3.818,13.007,8.654,4.929,5.623,P<0.05).The cumulative incidence of AECOPD and the cumulative incidence of rehospitalization in the observation group were lower than those in the control group (χ^(2)=4.325,4.145,P<0.05). Conclusion Breviscapine injection can significantly improve the curative efficacy,lung function and quality of life. Breviscapine injection exerts therapeutic effect by inhibiting TGF-β1/Smad pathway.

关 键 词：慢性阻塞性肺疾病 灯盏花素 肺功能 转化生长因子-β1 

分 类 号：R259[医药卫生—中西医结合]